| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11886-011-0239-5 |
| P698 | PubMed publication ID | 22193845 |
| P2093 | author name string | Wengen Chen | |
| Vasken Dilsizian | |||
| P2860 | cites work | Pharmacokinetics and normal scintigraphic appearance of 99mTc aprotinin | Q81743762 |
| Use of Florbetapir-PET for Imaging β-Amyloid Pathology | Q22253015 | ||
| In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18) | Q24630918 | ||
| Molecular mechanism of Thioflavin-T binding to amyloid fibrils | Q28279924 | ||
| Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B | Q29012704 | ||
| Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent--a pilot study. | Q34113947 | ||
| Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis | Q34147275 | ||
| Radioimmunodetection of amyloid deposits in patients with AL amyloidosis | Q34193315 | ||
| Primary systemic amyloidosis: clinical and laboratory features in 474 cases. | Q34320169 | ||
| Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component | Q34351246 | ||
| Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans | Q34415207 | ||
| Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis | Q34977930 | ||
| Micro-imaging of amyloid in mice. | Q35652050 | ||
| Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies. | Q35669845 | ||
| Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibody | Q35785799 | ||
| Non-invasive assessment of the presence and severity of cardiac amyloidosis. A study in familial amyloidosis with polyneuropathy by cross sectional echocardiography and technetium-99m pyrophosphate scintigraphy | Q36752185 | ||
| Cardiac amyloidosis: approaches to diagnosis and management | Q37654514 | ||
| Variation of heart-to-mediastinal ratio in (123)I-mIBG cardiac sympathetic imaging: its affecting factors and potential corrections | Q37827405 | ||
| Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy | Q40388294 | ||
| Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic innervation in patients with AL (primary) amyloidosis | Q44047898 | ||
| [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients | Q46151754 | ||
| Synthesis of 18F-labelled 2-(4'-fluorophenyl)-1,3-benzothiazole and evaluation as amyloid imaging agent in comparison with [11C]PIB. | Q46160939 | ||
| Preliminary experience of 99mTc-Aprotinin scintigraphy in amyloidosis. | Q53455054 | ||
| 99mTc-aprotinin scintigraphy in amyloidosis. | Q53659713 | ||
| Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy | Q56986496 | ||
| Antimyosin Scintigraphy for Detection of Cardiac Amyloidosis | Q57905116 | ||
| Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin | Q58030668 | ||
| Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation | Q64361284 | ||
| Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis | Q67271832 | ||
| Amyloidosis of heart and liver: comparison of Tc-99m pyrophosphate and Tc-99m methylene diphosphonate for detection | Q67298587 | ||
| [Cardiac involvement in systemic amyloidosis: myocardial scintigraphic evaluation] | Q70110276 | ||
| Utility of technetium Tc 99m pyrophosphate bone scanning in cardiac amyloidosis | Q70181495 | ||
| Electrocardiography and Doppler echocardiography in secondary (AA) amyloidosis | Q71015688 | ||
| Iodine-123 metaiodobenzylguanidine scintigraphic assessment of myocardial sympathetic innervation in patients with familial amyloid polyneuropathy | Q71975716 | ||
| Cardiac sympathetic denervation in transthyretin-related familial amyloidotic polyneuropathy: detection with iodine-123-MIBG | Q72284009 | ||
| Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the noninvasive diagnosis of cardiac amyloidosis | Q72925175 | ||
| Myocardial Tc-99m MDP uptake on a bone scan in senile systemic amyloidosis with cardiac involvement | Q73107127 | ||
| Cardiac sympathetic denervation in familial amyloid polyneuropathy assessed by iodine-123 metaiodobenzylguanidine scintigraphy and heart rate variability | Q77313169 | ||
| Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis | Q80341044 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 226-233 | |
| P577 | publication date | 2012-04-01 | |
| P1433 | published in | Current cardiology reports | Q26842345 |
| P1476 | title | Molecular imaging of amyloidosis: will the heart be the next target after the brain? | |
| P478 | volume | 14 |
| Q37054790 | (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses |
| Q43161462 | Amyloid PET imaging: applications beyond Alzheimer's disease |
| Q26750249 | Amyloid Proteins and Their Role in Multiple Sclerosis. Considerations in the Use of Amyloid-PET Imaging |
| Q88008461 | Clinical Phenotyping of Transthyretin Cardiac Amyloidosis with Bone-Seeking Radiotracers in Heart Failure with Preserved Ejection Fraction |
| Q28073135 | Clinical Utility and Future Applications of PET/CT and PET/CMR in Cardiology |
| Q37699944 | Diffuse Hepatic and Spleen Uptake of Tc-99m MDP on Bone Scintigraphy Resembling Liver-Spleen Scintigraphy in a Patient of Plasma Cell Tumor. |
| Q33793266 | Dual-Energy SPECT and the Development of Peptide p5+14 for Imaging Amyloidosis. |
| Q47140227 | Evaluation of the effect of D-amino acid incorporation into amyloid-reactive peptides |
| Q26827340 | Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment |
| Q34448455 | Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment |
| Q38928383 | Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment |
| Q58274881 | Isolated heart transplantation for familial transthyretin (TTR) V122I cardiac amyloidosis |
| Q97886126 | Multi-Modality Imaging in Dilated Cardiomyopathy: With a Focus on the Role of Cardiac Magnetic Resonance |
| Q36769236 | Re-evaluating the potentials and limitations of (99m)Tc-aprotinin scintigraphy for amyloid imaging |
| Q39114674 | Role of Imaging in Evaluating Infiltrative Heart Disease. |
| Q34392552 | Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques |
| Q43187527 | Shoulder pad sign and asymptomatic hypercalcemia in a patient with end-stage kidney disease |
| Q51829619 | Standardization of 99mTechnetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis. |
| Q30251986 | Systemic amyloidosis |
| Q41693071 | The Potential of Clinical Phenotyping of Heart Failure With Imaging Biomarkers for Guiding Therapies: A Focused Update |
| Q39144999 | The toxicity mechanisms of action of Aβ25-35 in isolated rat cardiac myocytes. |
| Q36408438 | Transthyretin (TTR) cardiac amyloidosis |
Search more.